PUBLICATIONS DISCUSSED BY STEPHANIE A GREGORY, MD

Abstracts listed in order of their review in the audio program

Abstract 125. Goy A et al. Durable responses with bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Updated time-to-event analyses of the multicenter PINNACLE study. Proc ASH 2007.

Abstract 2578. Drach J et al. Bortezomib, rituximab, and dexamethasone (BORID) as salvage treatment in relapsed/refractory mantle cell lymphoma: Sustained disease control in patients achieving a complete remission. Proc ASH 2007.

Abstract LB1. Geisler CH et al. Mantle cell lymphoma can be cured by intensive immunochemotherapy with in-vivo purged stem-cell support; Final report of the Nordic Lymphoma Group MCL2 study. Proc ASH 2007.

Abstract 1362. Martin P et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: Overall survival exceeding seven years in a large cohort of patients managed primarily with conservative therapies. Proc ASH 2007.

Abstract 385. Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas - First interim results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Proc ASH 2007.

Abstract 1351. Kahl B et al. Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Proc ASH 2007.

Abstract 643. Hagenbeek A et al. ⁹⁰Y-ibritumomab tiuxetan (Zevalin^®) consolidation of first remission in advanced stage follicular non-Hodgkin’s lymphoma: First results of the international randomized Phase 3 First-Line Indolent Trial (FIT) in 414 patients. Proc ASH 2007.

Abstract 1360. Gregory SA et al. A prospective study evaluating the safety and efficacy of combination therapy with fludarabine plus mitoxantrone followed by yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin^®) and maintenance rituximab as front line therapy for patients with intermediate or high risk follicular non-Hodgkin’s lymphoma. Proc ASH 2007.

Abstract 389. Smith MR et al. Phase II study of R-CHOP followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499. Proc ASH 2007.

Abstract 387. Epner EM et al. A multi center trial of hyperCVAD+Rituxan in patients with newly diagnosed mantle cell lymphoma. Proc ASH 2007.